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Abstract
Obesity and related metabolic disorders such as insulin resistance and type 2 diabetes are associated with a low-grade
inflammatory state possibly through changes in gut microbiota composition and the development of higher plasma
lipopolysaccharide (LPS) levels, i.e. metabolic endotoxemia. Various phytochemical compounds have been investigated as
potential tools to regulate these metabolic features. Humulus lupulus L. (hops) contains several classes of compounds with
anti-inflammatory potential. Recent evidence suggests that hops-derived compounds positively impact adipocyte
metabolism and glucose tolerance in obese and diabetic rodents via undefined mechanisms. In this study, we found
that administration of tetrahydro iso-alpha acids (termed META060) to high-fat diet (HFD)-fed obese and diabetic mice for 8
weeks reduced body weight gain, the development of fat mass, glucose intolerance, and fasted hyperinsulinemia, and
normalized insulin sensitivity markers. This was associated with reduced portal plasma LPS levels, gut permeability, and
higher intestinal tight junction proteins Zonula occludens-1 and occludin. Moreover, META060 treatment increased the
plasma level of the anti-inflammatory cytokine interleukin-10 and decreased the plasma level of the pro-inflammatory
cytokine granulocyte colony-stimulating factor. In conclusion, this research allows us to decipher a novel mechanism
contributing to the positive effects of META060 treatment, and supports the need to investigate such compounds in obese
and type 2 diabetic patients.
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Introduction
Obesity is characterized by a massive expansion of the adipose
tissue [1]. Growing evidence suggests that obesity and related
metabolic disorders such as insulin resistance, type 2 diabetes, and
cardiovascular diseases are associated with a low-grade inflamma-
torystate [2].Recently, theoriginofthisinflammatorytonehasbeen
linked to the development of higher plasma lipopolysaccharide (LPS)
levels, or metabolic endotoxemia [3,4]. LPS is a cell-wall component
of Gram-negative bacteria considered as the most potent inducer of
inflammation. We and others have demonstrated a tight relationship
between metabolic endotoxemia, changes in gut microbiota
composition, the development of glucose intolerance, insulin
resistance and type 2 diabetes in both rodents and humans [3–13].
Numerous phytochemical compounds have been studied as
potential tools to regulate glucose homeostasis, adipose tissue
development and inflammatory tone. Among these is the widely
studied plant genus Humulus (belonging to the family of
Cannabaceae) [14]. The species Humulus lupulus L. (hops), is a
plant that has been used for medicinal purposes for centuries and
contains several classes of compounds with anti-inflammatory
potential [14–16]. Growing evidence suggests that tetrahydro iso-
alpha acids (termed META060) derived from hops inhibited LPS–
stimulated prostaglandin E2 (PGE2) production, nitric oxide
formation, cyclooxygenase 2 (COX-2) abundance, and the pro-
inflammatory transcription factors nuclear factor kappa B (NF-kB)
pathway in macrophages [15]. Moreover, these compounds exert
anti-inflammatory activity on LPS-stimulated tumor necrosis
factor alpha (TNF-a) and interleukin-6 (IL-6) production in
isolated peripheral blood mononuclear cells [16]. In addition to
these effects hops-derived compounds (including iso-alpha acids)
have been found to block TNF-a-induced production of IL-6 and
to inhibit the transactivation of NF-kB, activator protein-1 (AP-1),
and cAMP-response element-binding protein (CREB) in fibro-
blasts [17]. More recently, it has been proposed that hops has
positive impact on adipocyte metabolism [18] and glucose
tolerance in obese and diabetic rodents; however, the exact
mechanisms explaining these effects are not well characterized
[19,20]. Therefore, in the present study we investigated the impact
of a well-defined hop extract (META060) on body weight gain, fat
mass development, glucose homeostasis and gut barrier function
markers in diet-induced obese and type 2 diabetic mice.
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Materials
META060 was supplied by Metagenics, Inc. (Gig Harbor, WA,
USA); the chemical composition of META060 has been described
previously [15,16]. C57BL/6J mice were obtained from Charles
River Laboratories International, Inc. (Brussels, Belgium).
Mice
A set of 10-week-old C57BL/6J mice (30 mice, n=10/group)
were housed in groups of three or four mice/cage, with free access
to food and water. Mice were fed a control diet (CT) consisted of
normal chow (Research diet, New Brunswick, NJ, USA), a high-fat
diet (HFD) (D12492, Research diet) containing 45% fat (kcal/
100 g) and 20% carbohydrates (kcal/100 g), or a high-fat diet
supplemented with 0.1% META060 (HFD-META060). Treat-
ment continued for 8 weeks. Food intake was recorded as a
cumulative intake over a week and once a week during the
treatment period.
This study was performed in strict accordance with the
guidelines of the local ethics committee (ethical committee of the
Universite ´ catholique de Louvain for animal experiments
specifically approved this study that received the agreement nu
2010/UCL/MD/022) and are in accordance with the European
recommendation 2007/526/CE, translated in the Belgian Law of
April 6, 2010, regarding the protection of laboratory animals. The
laboratory has received the agreement number LA1230314 from
the Ministry of Agriculture. All the animals are housed in cages
with enrichment in a controlled light/dark cycle, temperature and
humidity environment. Every effort was made to minimize
suffering during manipulations and oral gavage. Food was
removed 2 h after the onset of the daylight cycle and mice were
fasted 6-h as previously described [3,4], then all the animals have
been anesthetized with isoflurane (ForeneH, Abbott, Queen-
borough, Kent, England) before exsanguination and tissue
sampling, then mice were killed by cervical dislocation.
Oral glucose tolerance test
Oral glucose tolerance tests were performed after 7 weeks of
treatment. Food was removed 2 h after the onset of the daylight
cycle and mice were treated after a 6-h fasting period as previously
described [3,4].
Tissue sampling
Mice were anesthetized with isoflurane (ForeneH, Abbott,
Queenborough, Kent, England) after a 6-h fasting period. Blood
samples and tissues were harvested for further analysis. Epididy-
mal, subcutaneous and visceral adipose deposits were precisely
dissected and weighed. The jejunum segments and adipose tissues
were immediately immersed in liquid nitrogen and stored at
280uC for further analysis.
Biochemical analyses
Portal plasma LPS concentration was measured by using
Endosafe-MCS (Charles River Laboratories, Lyon, France) based
on the Limulus amaebocyte Lysate (LAL) kinetic chromogenic
methodology that measures color intensity directly related to the
endotoxin concentration in a sample as previously described [5].
Serum were diluted 1/10 with endotoxin free buffer to minimize
interferences in the reaction (inhibition or enhancement) and
heated 15 min at 70uC. Each sample was diluted 1/70 or 1/100
with endotoxin-free LAL reagent water (Charles River Laborato-
ries) and treated in duplicate and two spikes for each sample were
included in the determination. All samples have been validated for
the recovery and the coefficient variation. The lower limit of
detection was 0.005 EU/ml.
Plasma insulin concentration was determined in 25 ml of plasma
using an ELISA kit (Mercodia, Upssala, Sweden) as previously
described [5,21].
Plasma IL-10 and granulocyte colony-stimulating factor (G-
CSF) were determined in duplicate by using a Bio-Plex Pro Assays
kit (Bio-Rad, Nazareth, Belgium) and measured by using Luminex
(Bio-Rad Bioplex, Bio Rad) following the manufacturer’s instruc-
tions.
Intestinal phosphatase alkaline (IAP) activity was measured in
30 mg of jejunum tissue following the kinetic chromogenic
methodology that measures color intensity directly related to the
kinetic hydrolysis (30 min) of the p-nitrophenylphosphate (pNNP)
in p-nitrophenol (pNP) as previously described [22].
Occludin immunoblot analysis
Samples (30 mg) were homogenized with TissueLyser II
(Qiagen) and lysed in buffer (100 mM KCl, 3 mM NaCl,
3.5 mM MgCl2, and 10 mM HEPES; pH 7.4) containing 1%
Triton X-100, 1% protease inhibitor cocktail (P8340, Sigma-
Aldrich, Saint Louis, USA), and phosphatase inhibitors (100 mM
NaF and 200 mM Na3VO4) and incubated 30 min at 4uC. After
centrifugation (15000 g for 15 min at 4uC) the pellet was dissolved
in SDS buffer (4% (wt/vol) SDS, 0.75 M Tris (pH 8.8), 15%
glycerol, and 20 mM DTT) and heated 10 min at 65uC thereby
corresponding to the insoluble fraction. The protein concentration
was measured by the Bradford method. Proteins (60 mg/lane) were
fractionated on a 8% SDS-PAGE gel and transferred to
nitrocellulose membranes (Hybond-ECL, Amersham). Mem-
branes were blocked in 0,1% Tween 20 in TBS with 5% (wt/
vol) nonfat dry milk for 2 h at room temperature and then probed
with rabbit anti-Occludin (Invitrogen) (0,5 mg/ml) antibodies
overnight at 4uC or with mouse anti-beta actin (Abcam) (1/
10000) for 1 hour. After washing, membranes are incubated for
1 h with HRP-conjugated secondary antibodies (goat anti-rabbit
1:10,000, Chemicon or rabbit anti-mouse 1:2500, Dako).
Immunocomplexes were visualized using ECL Western blotting
detection reagents (SuperSignal West Pico Substrate, Thermo
Scientific).
RNA preparation and real-time qPCR analysis
Total RNA was prepared from tissues using TriPure reagent
(Roche). Quantification and integrity analysis of total RNA was
performed by running 1 ml of each sample on an Agilent 2100
Bioanalyzer (Agilent RNA 6000 Nano Kit, Agilent). cDNA was
prepared by reverse transcription of 1 mg total RNA using a
Reverse Transcription System kit (Promega, Leiden, The Nether-
lands). Real-time PCRs were performed with the StepOnePlus
TM
real-time PCR system and software (Applied Biosystems, Den
Ijssel, The Netherlands) using Mesa Fast qPCR
TM (Eurogentec,
Seraing, Belgium) for detection according to the manufacturer’s
instructions. RPL19 RNA was chosen as the housekeeping gene.
Primer sequences for RPL-19, ZO-1 and Occludin were
previously described [7]. All samples were run in duplicate in a
single 96-well reaction plate, and data were analyzed according to
the 2
2DCT method. The identity and purity of the amplified
product was checked through analysis of the melting curve carried
out at the end of amplification.
Statistical analyses
The data are expressed as the mean 6 SEM. Differences
between groups were assessed using one-way ANOVA, followed
by post-hoc Tukey-tests or two-tailed Student’s t-test. Data were
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(GraphPad Software, San Diego, CA, USA). The results were
considered statistically significant at P,0.05.
Results
META060 reduces high-fat diet-induced body weight
gain and fat mass development
We found that mice fed with a high-fat diet (HFD mice)
significantly and progressively gained weight throughout the study
as compared to control (CT) mice (Figure 1A and inset, Figure S1).
Interestingly, HFD-META060 mice exhibited significant reduced
body weight gain than HFD mice (Figure 1A), whereas food intake
was not affected by the treatment (Figure 1B). Similarly, both
subcutaneous and visceral adipose depots were significantly lower
in HFD-META060 mice than in HFD mice (Figure 1C and D),
whereas a trend toward a decrease was found for the epididymal
fat tissue that remained significantly higher in HFD-META060
than in the CT mice (Figure 1E). Overall, META060 significantly
decreased the total adiposity as compared to the HFD-fed mice
(Figure 1F), although this parameter was not fully returned to the
levels seen in CT mice.
META060 improves glucose tolerance in obese and type
2 diabetic mice
HFD feeding promoted type 2 diabetes and glucose intolerance
as shown by the significantly higher plasma glucose levels in the
fasting state and following an oral glucose load (Figure 2A). HFD-
META060 feeding improved glucose homeostasis as shown by the
normalized fasting glycemia and the improved glucose tolerance
(Figure 2A). In addition, area under the curves (AUC) measured
during 2 h following the oral glucose challenge was equivalent
between CT mice and HFD-META060 mice, whereas AUC in
HFD mice was significantly increased compared to the other 2
groups (Figure 2B).
META060 protects against high-fat diet-induced insulin
resistance and fasted hyperinsulinemia in obese and type
2 diabetic mice
Fasting hyperinsulinemia and insulin resistance are both
hallmark of obesity and type 2 diabetes. Here, we found that
HFD-META060 mice were completely resistant to the high-fat
diet-induced hyperinsulinemia in both fasting and following oral
glucose load (Figure 3A and B). More importantly, HFD mice
exhibited a 4-fold increase in the insulin resistance index (HOMA-
IR), whereas HFD-META060 and CT mice were resistant to the
development of insulin resistance, as shown by the similar
HOMA-IR scores (Figure 3C).
META060 modulates plasma cytokines in obese and type
2 diabetic mice
Given that IL-10 has been found to protect against diet-induced
insulin resistance [23] and to be positively associated with insulin
sensitivity [24], we measured this cytokine in the plasma. We
found that in HFD-META060 mice plasma IL-10 (pg/ml)
increased by about 46% (CT 80.667.5, HFD 72.763.9, HFD-
META060 106.3613.2, HFD vs HFD-META060: P=0.07). We
next assayed plasma levels of the cytokine G-CSF, which has been
considered as a key pro-inflammatory regulator in diet-induced
obese mice [25,26]. We observed that HFD feeding increased G-
CSF levels (pg/ml) by about two-fold as compared to CT mice
(P=0.06), whereas HFD-META060 mice exhibited normalized
levels (CT 5365.1, HFD 105.7628, HFD-META060 50.663.6,
HFD vs HFD-META060: P=0.055).
META060 reduces high-fat diet-induced metabolic
endotoxemia in obese and type 2 diabetic mice
We previously found that metabolic endotoxemia (increased
plasma LPS levels) contributed to the alteration of glucose
tolerance and triggered insulin resistance [3]. In addition, plasma
LPS correlated with plasma glucose, fasting insulinemia and
predicted type 2 diabetes incident [6,13,27,28]. Therefore, we
measured the impact of META060 on high-fat diet induced
metabolic endotoxemia. We found that HFD feeding significantly
increased plasma LPS levels, and HFD-META060 fed mice were
resistant to the HFD induced metabolic endotoxemia (Figure 4).
META060 tends to increase intestinal phosphatase
alkaline (IAP) activity
Among the mechanisms involved in decreased plasma LPS,
several studies have demonstrated that IAP can be considered as a
protective factor involved not only in gut barrier integrity but also
in LPS detoxification [10,29–31]. We found that HFD-META060
group increase IAP activity by about 25% as compared to HFD
group (CT 14.4561.34, HFD 13.9860.69, HFD-META060
17.1861.42 nmoles of hydrolyzed substrates/min per mg of
proteins, HFD vs HFD-META060: P=0.07).
META060 reduces gut permeability via occludin and ZO-
1 tight-junction proteins modulation in high-fat diet-
induced obese and type 2 diabetic mice
In addition to the IAP activity, we and others have previously
shown that gut barrier function controls plasma LPS levels in both
diet-induced and genetically obese and type 2 diabetic mice,
possibly through the up-regulation of two key tight junctions
proteins, zonula occludens-1 (ZO-1) and occludin [4,7,8,10,11].
Here we found that HFD-META060 mice displayed a 2- to 3-fold
increase in ZO-1 and occludin mRNA levels, respectively
(Figure 5A and C). Tight junctions are structurally characterized
as soluble or insoluble proteins by their partition into Triton X-
100 buffer [11]. As shown on figure 5B, Occludin expression is
lower in the insoluble protein fractions of HFD mice than HFD-
META060, and control mice. These findings strongly suggest a
shift of intestinal junctional protein from the cytoskeleton, causing
a decrease in paracellular sealing, and thereby higher gut
permeability in HFD mice.
Together with the plasma LPS levels, these data indicate that
META060 feeding has positive impact on the gut barrier function.
Discussion
In the present study, we characterized the impact of Humulus
lupulus L.-derived compounds (i.e. META060) on several
metabolic features that are associated with high-fat diet feeding.
First, META060 treatment significantly reduced body weight
gain and fat mass development following 8 weeks of high-fat diet.
Second, META060 protected mice against diet-induced fasting
hyperglycemia and hyperinsulinemia. Third, these effects were
associated with improved glucose tolerance and normalized
insulin sensitivity. In addition, we discovered the improvement of
high-fat diet-induced metabolic endotoxemia to be a novel
mechanism contributing to META060’s metabolic effects. Given
that these markers are all hallmarks of type 2 diabetes, these
findings strongly support the role of META060 in the prevention
of this disease.
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high-fat diet-induced body weight gain and fat mass development.
Given the fact that food intake was not different between HFD
and HFD-META060 groups, it is likely that META060
contributed to the reduced fat mass development and thereby
preventing body weight gain. It has been recently proposed that
hops iso-alpha acids, structurally similar to META060, increase
liver fatty acid oxidation and normalize adipocyte hypertrophy via
the co-activation of PPARa and PPARc [19,20]. META060
(tetrahydro iso-alpha acids) may also possess such biological activity
and this warrants future studies.
However, even though we observed lower body weight and fat
mass in HFD-META060 mice, the adiposity index remained
significantly higher than in normal chow fed mice. Nevertheless,
fasting plasma glucose levels were completely normalized and, in
accordance with this effect, glycemia returned to the basal level
Figure 1. META060 reduces high-fat diet-induced body weight gain and fat mass development. (A) Body weight gain (g) evolution, inset
correspond to total body weight gain, (B) cumulative food intake (g), (C) subcutaneous, (D) visceral, (E) epididymal adipose tissues weight, and (F)
adiposity index (corresponding to the sum of the three adipose depots) expressed as the percentage of total body weight of mice fed a control diet
(CT), high-fat diet (HFD) or high-fat diet supplemented with 0.1% META060 (HFD-META060). n=10 mice/group. Data are expressed as mean 6 SEM.
Different superscript letters were significantly different (P,0.05) according to one-way ANOVA. Interaction Treatment6Time P,0.0001; Treatment
P,0.0001; Time P,0.0001. *P,0.05 HFD versus CT, $P,0.05 HFD-Meta versus HFD, #P,0.05 HFD-Meta versus CT according to Two-way ANOVA.
doi:10.1371/journal.pone.0033858.g001
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observed in the control mice. Importantly, HFD-META060 mice
were completely resistant to the diet-induced hyeprinsulinemia.
This effect was corroborated by the absence of insulin resistance in
HFD-META060 mice compared to the HFD mice which
developed a marked insulin resistance. Therefore, these results
strongly suggest that tetrahydro iso-alpha acids exert beneficial
effect on plasma glucose, inflammation and insulin resistance
independently of body weight loss or lower body fat accumulation.
In accordance with this hypothesis, it has been previously
demonstrated that these compounds inhibit LPS–stimulated
PGE2, TNF-a, IL-6, nitric oxide and COX-2 abundance, as well
as NF-kB pathway [15–17]. It is worth noting that previous study
has shown that mice treated for 21 days with Meta060 did not
exhibited any changes in body weight gain and food intake [32],
further supporting that these compounds are not acting through
food intake and or body weight-dependent mechanisms.
For instance, the study of VO2 and VCO2 by indirect
calorimetry at rest and during physical activity could constitute
one interesting perspective to investigate further.
Previous studies have shown in diet-induced and genetic obesity
models that low-grade inflammatory tone causes insulin resistance
[1,33] which favors hyperinsulinemia and excessive hepatic and
adipose tissue lipid storage [34,35]. Extensive research has been
dedicated to unravel the effects of inflammatory reactions on
energy metabolism; however, the triggering factors linking high-fat
diet-induced metabolic syndrome are not fully determined.
Accumulating evidence suggests that various hops-derived com-
pounds abolished LPS-induced inflammation via several mecha-
nisms including NF-kB-dependent pathways [15–18,32]. In the
present study, we believe this important property contributes to
the improved phenotype observed in HFD-META060 mice.
Plasma levels of the anti-inflammatory cytokine IL-10 have been
found to positively correlate with insulin sensitivity [24] and IL-10
treatment protects against diet-induced insulin resistance [23]. In
the present study, META060 treatment increased plasma IL-10 by
about 46%. Although this increase was not statistically significant,
we believe that it contributed to the improved phenotype
observed. We also measured plasma levels of the pro-inflammatory
cytokine G-CSF. G-CSF is known to exacerbate underlying
inflammatory diseases [26] and increases in diet-induced obese
mice [25]. We found a 2-fold decrease in G-CSF plasma levels in
HFD-META060 mice compared to HFD mice.
In addition to these effects on the inflammatory tone, we
identified that META060 feeding abolished high-fat diet-induced
metabolic endotoxemia. Growing evidence shows that obesity and
type 2 diabetes are associated with an altered gut microbiota
composition and higher plasma LPS levels, although the
Figure 2. META060 improves glucose tolerance in obese and type 2 diabetic mice. (A) Plasma glucose levels and (B) area under the curve
following 2 g/kg glucose oral challenge measured in freely moving mice fed a CT, HFD or HFD-META060 diet. Data are mean 6 SEM. n=10 mice/
group. *P,0.05 HFD versus HFD-META060,
#P,0.05 HFD versus CT diet determined by a two-tailed Student’s t-test. Data with different superscript
letters were significantly different (P,0.05) according to one-way ANOVA.
doi:10.1371/journal.pone.0033858.g002
Figure 3. META060 protects against high-fat diet-induced insulin resistance and fasting hyperinsulinemia in obese and type 2
diabetic mice. (A) Fasted plasma insulin levels, (B) glucose-induced insulin secretion (15 min after an oral glucose load), and (C) insulin resistance
index (Homeostasis model assessment of insulin resistance (HOMA-IR) measured in mice fed a CT, HFD or HFD-META060 diet. Data are mean 6 SEM.
n=10 mice/group. Data with different superscript letters were significantly different (P,0.05) according to one-way ANOVA.
doi:10.1371/journal.pone.0033858.g003
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worth mentioning that obesity has been found to be associated
with altered gut barrier function [4,7,8,10,11]. The maintenance
on the gut barrier function is dependent of the tight junction
proteins complex including two key markers ZO-1 and Occludin
[36,37]. Furthermore, several studies have shown that the
increased plasma LPS levels and gut permeability are explained
in part by the alteration of the expression of genes coding for tight
junction proteins (ZO-1 and occludin) [4,7,8,11]. In the present
study, both ZO-1 and occludin mRNA expressions were
significantly up-regulated following META060 treatment. In
addition to the mRNA expression, we investigated Occludin
protein distribution through its solubility profile. HFD mice
exhibited decreased Occludin expression in the insoluble fraction,
thereby suggesting that Occludin is delocalized from the junction
protein complex associated with the cytoskeleton [11,38] leading
to altered gut barrier function. Therefore, we postulate that the
increased Occludin protein levels found in the insoluble fraction
contribute to the improved gut barrier function, hence unraveling
the mechanism involved in the reduced metabolic endotoxemia
and inflammation observed in HFD-META060 treated mice. In
addition to these findings, we demonstrated that META060
treatment increases intestinal alkaline phosphatase activity by
about 25%. Although, this effect did not reach significance, we
may not rule out that such increased activity throughout the entire
gastrointestinal tract not only contributes to reinforcing the gut
barrier but might also be involved in LPS detoxification [30].
Therefore, we hypothesized that the improved metabolic
endotoxemia could be due to several effects of META060 on
gut barrier. Several lines of evidence are supporting this
hypothesis. For instance, tight junction complexes are regulated
through several canonical pathways such as the mitogen-activated
protein (MAP) kinase and NF-kB pathways [39,40], and
META060 has been shown to interact with these pathways
[15,16]. Moreover, LPS has been proposed as a factor involved in
the development of gut barrier disruption per se [41,42], and hops
iso-alpha acids and META060 have been shown to abolish LPS-
induced inflammation and NF-kB transcription [15–17,32]
In conclusion, META060 improves diet-induced obesity, fat
mass development and associated metabolic disorders (glucose
intolerance, insulin resistance). More importantly, META060
protects mice against high-fat diet-induced metabolic endotox-
emia, a result associated with improved gut barrier markers
(Occludin distribution and IAP) and lower inflammatory tone.
This research allows us to decipher a novel mechanism
contributing to the positive effects of tetrahydro iso-alpha acids
treatment. Altogether, these data support the need to test this
compound in obese and type 2 diabetic patients.
Figure 4. META060 reduces high-fat diet-induced metabolic
endotoxemia in obese and type 2 diabetic mice. (A) Portal
plasma lipopolysaccharide (LPS) levels measured in mice fed a CT, HFD
or HFD-META060 diet. Data are mean 6 SEM. n=10 mice/group. Data
with different superscript letters were significantly different (P,0.05)
according to one-way ANOVA.
doi:10.1371/journal.pone.0033858.g004
Figure 5. META060 increases occludin, ZO-1 tight-junction proteins mRNA expression and improves Occludin protein distribution
in high-fat diet-induced obese and type 2 diabetic mice. (A) Zonula occludens (ZO-1) and (C) occludin mRNA expression levels, (B)
representative blot of Occludin protein expression from insoluble cellular fraction in the jejunum of mice fed a CT, HFD or HFD-META060 diet. Actin
was used as loading control (n=5 mice/group). mRNA data are mean 6 SEM. n=10 mice/group. Data with different superscript letters were
significantly different (P,0.05) according to one-way ANOVA.
doi:10.1371/journal.pone.0033858.g005
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Figure S1 META060 reduces high-fat diet-induced body
weight gain. Body weight evolution (g) of mice fed a control diet
(CT), high-fat diet (HFD) or high-fat diet supplemented with 0.1%
META060 (HFD-META060). n=10 mice/group. Data are
expressed as mean 6 SEM.
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